Oxford Drug Design announces initial in vivo validation of novel oncology therapeutic mechanism
Appoints oncologist Prof. Sarah Blagden to its Scientific Advisory Board. Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering […]
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy. The CRUK (Cancer Research UK) Scotland Institute […]